Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Intangibles (2016 - 2022)

Historic Intangibles for Summit Therapeutics (SMMT) over the last 7 years, with Q3 2022 value amounting to $8.0 million.

  • Summit Therapeutics' Intangibles fell 2503.77% to $8.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $8.0 million, marking a year-over-year decrease of 2503.77%. This contributed to the annual value of $10.4 million for FY2021, which is 969.17% down from last year.
  • Latest data reveals that Summit Therapeutics reported Intangibles of $8.0 million as of Q3 2022, which was down 2503.77% from $8.9 million recorded in Q2 2022.
  • In the past 5 years, Summit Therapeutics' Intangibles registered a high of $21.0 million during Q1 2018, and its lowest value of $8.0 million during Q3 2022.
  • Over the past 5 years, Summit Therapeutics' median Intangibles value was $12.5 million (recorded in 2019), while the average stood at $12.7 million.
  • Per our database at Business Quant, Summit Therapeutics' Intangibles soared by 38712.12% in 2018 and then plummeted by 3520.79% in 2019.
  • Over the past 5 years, Summit Therapeutics' Intangibles (Quarter) stood at $14.1 million in 2018, then dropped by 9.0% to $12.8 million in 2019, then fell by 9.99% to $11.5 million in 2020, then dropped by 9.69% to $10.4 million in 2021, then dropped by 23.53% to $8.0 million in 2022.
  • Its last three reported values are $8.0 million in Q3 2022, $8.9 million for Q2 2022, and $9.9 million during Q1 2022.